You think it going along fine and something bad happens. Frova seems like a good drug based on everything I have read. I have thought that sales would be increasing. Sounds like sales are not picking up as much as hoped. I hope we find that sales are increasing at a decent rate and the problem is ELN has a partner that is not doing a great job in selling the product. If Frova is superior to other medicines it will find the market. It just takes time. A good sales force makes a huge difference. The competition has a good sales force.
We have heard nothing about Crohn�s yet. It is interesting because I wanted to hear some news coming out of this meeting. Could happen on Wed. I understand that is when they will present. ELN was also scheduled to meet with the FDA on crohns. We have yet to hear the results of the meeting. We will surely hear something by the 21st about Crohns. The AGM would be a good time to reveal that information if it is positive.
This company will live or die based upon Antegren. Let�s all hope Antegren works as well as expected in MS.
Frova revs were $5.9 MM in Q2. Someone posted a couple of weeks ago that revs were ramping up very rapidly to $25 MM /qtr. (maybe as soon as Q4). Sure doesn't sound like it from the Vernalis release. You're right, if Frova is as good as it's hype, it will find the market. Still, a strong marketing partner is critical.